Stocktoria
Enliven Therapeutics, Inc. ELVN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-03-12
Enliven Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $85.9M | $80.8M | $64.6M | $31.0M | $38.4M |
| Operating income | -$119.7M | -$104.6M | -$83.5M | -$38.8M | -$51.4M |
| Income tax | $0 | $232,000 | $0 | $0 | — |
| Net income | -$103.7M | -$89.0M | -$71.6M | -$37.7M | -$51.4M |
| EPS (diluted) | $-1.83 | $-1.89 | $-2.01 | $-12.05 | $-2.37 |
| Operating cash flow | -$70.3M | -$73.2M | -$61.3M | -$32.1M | -$46.8M |
| Cash & equivalents | $98.9M | $124.1M | $100.1M | $75.5M | $48.3M |
| Total assets | $476.2M | $325.8M | $271.9M | $83.3M | $93.6M |
| Total liabilities | $16.6M | $15.9M | $26.0M | $10.4M | $7.6M |
| Shareholders' equity | $459.6M | $309.8M | $245.9M | -$76.8M | -$42.9M |
Source: SEC EDGAR filings · CIK 0001672619 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.